Johnson & Johnson started its stage 3 for the Covid-19 Vaccine

Market Trends - 24/09/2020

Johnson & Johnson started its stage 3 for the Covid-19 Vaccine

Johnson & Johnson announced yesterday that it has launched its stage three of trial testing of its possible coronavirus vaccine.

The Company is the fourth drug maker supported by Trump's government Covid-19 vaccine program Operation Warp Speed to enter the late-stage trial. Other companies include AstraZeneca, Moderna, and Pfizer.

According to the National Institute of Allergy and Infectious Diseases, the test will record up to 60,000 grown-up volunteers over 215 areas in the U.S. and additional countries. According to details of the test, which will conclude whether the vaccine is safe and useful, volunteers will be randomly picked to get a dose of the possible vaccine or a placebo.

Institute director Dr. Anthony Fauci said in a statement “Four COVID-19 vaccine candidates are in Phase 3 clinical testing in the United States just over eight months after SARS-CoV-2 was identified,” “This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry, and academia.”

He additionally stated “It is likely that multiple COVID-19 vaccine regimens will be required to meet the global need. The Janssen candidate has shown promise in early-stage testing and may be especially useful in controlling the pandemic if shown to be protective after a single dose.”

J&J, the parent company of Janssen, has said it is practicing the same technologies it used to create its trial Ebola vaccine.

Preliminary clinical research has revealed that J&J’s potential Covid-19 vaccine can create a promising outcome in nonhuman primates and hamsters. The European Centre for Disease Prevention and Control announced that as of Sep. 22, 2.9 million people had been infected with COVID-19 in Europe with Spain and France now witnessing daily cases increase – over the 10,000 marks. The race for the vaccine is on but we need to take into consideration that progress is still slow.

The above content is considered to be market commentary information and shall not be perceived as independent investment research or investment advice.


This website uses cookies to ensure best possible user experience. Read more